Jackson E K, Campbell W B
Hypertension. 1981 Jan-Feb;3(1):23-33. doi: 10.1161/01.hyp.3.1.23.
The effects of propranolol on angiotensin II (AII) enhancement of sympathetic nerve transmission were investigated in the in situ blood-perfused mesenteric vascular bed of the rat. Angiotensin II in subpressor concentrations (3 ng/ml) potentiated the vasoconstrictor responses to both sympathetic nerve stimulation (NS) and exogenous norepinephrine (NE). The dl-propranolol had no effect on the basal vasoconstrictor responses to NS and NE, yet inhibited the AII-enhanced vasoconstrictor responses to NS by 47% (p less than 0.05) and 81% (p less than 0.001) at 100 and 300 ng/ml respectively. In contrast, the potentiation of NE responses by AII was unaffected by propranolol. A similar blockade of AII enhancement of NS was observed with the d-isomer of propranolol. Dibucaine (300 ng/ml), a local anesthetic, failed to alter the basal or AII-enhanced responses to either NS or NE. Indomethacin, a prostaglandin synthetase inhibitor (5 mg/kg, s.c.), abolished the inhibitory effect of dl-propranolol on AII enhancement of NS. Prostaglandin E2 (PGE2), but not prostaglandin I2, (3 ng/ml) inhibited AII enhancement of NS without altering the basal response to NS or NE in indomethacin-pretreated animals. Intraarterial infusions of dl-propranolol, d-propranolol, AII, and dl-propranolol-plus-AII into the superior mesenteric artery increased mesenteric venous PGE2 concentrations from 216 +/- 33 to 355 +/- 33 (p less than 0.01), 328 +/- 44 (p less than 0.05), 325 +/- 27 (p less than 0.02), and 407 +/- 44 pg/ml (p less than 0.01) respectively. We conclude that propranolol antagonizes AII enhancement of NS by increasing prostaglandin levels in vascular tissue. Furthermore, these findings suggest that propranolol may exert its antihypertensive effect through the release of prostaglandins when used in therapeutic doses in excess of those required for beta-adrenergic blockade.
在大鼠原位血液灌注肠系膜血管床中研究了普萘洛尔对血管紧张素II(AII)增强交感神经传递的作用。低于升压浓度(3 ng/ml)的血管紧张素II增强了对交感神经刺激(NS)和外源性去甲肾上腺素(NE)的血管收缩反应。消旋普萘洛尔对NS和NE的基础血管收缩反应无影响,但分别在100和300 ng/ml时,抑制了AII增强的对NS的血管收缩反应的47%(p<0.05)和81%(p<0.001)。相比之下,普萘洛尔不影响AII对NE反应的增强作用。普萘洛尔的右旋异构体也观察到对AII增强NS的类似阻断作用。局部麻醉剂丁卡因(300 ng/ml)未能改变对NS或NE的基础或AII增强反应。前列腺素合成酶抑制剂吲哚美辛(5 mg/kg,皮下注射)消除了消旋普萘洛尔对AII增强NS的抑制作用。在吲哚美辛预处理的动物中,前列腺素E2(PGE2)而非前列腺素I2(3 ng/ml)抑制了AII增强的NS,而不改变对NS或NE的基础反应。向上肠系膜动脉内输注消旋普萘洛尔、右旋普萘洛尔、AII和消旋普萘洛尔加AII,使肠系膜静脉PGE2浓度分别从216±33升高至355±33(p<0.01)、328±44(p<0.05)、325±27(p<0.02)和407±44 pg/ml(p<0.01)。我们得出结论,普萘洛尔通过增加血管组织中的前列腺素水平来拮抗AII增强的NS。此外,这些发现表明,当普萘洛尔以超过β-肾上腺素能阻断所需的治疗剂量使用时,可能通过释放前列腺素发挥其降压作用。